-
Signature
-
Michael J. Farrell, Chief Executive Officer
-
Stock symbol
-
RMD
-
Transactions as of
-
Nov 7, 2024
-
Transactions value $
-
-$4,584,243
-
Form type
-
4
-
Date filed
-
11/12/2024, 05:37 PM
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
RMD |
ResMed Common Stock |
Options Exercise |
$1.25M |
+14.7K |
+3.16% |
$84.98 |
479K |
Nov 7, 2024 |
Direct |
F1, F2 |
| transaction |
RMD |
ResMed Common Stock |
Sale |
-$3.62M |
-14.7K |
-3.07% |
$246.26 |
464K |
Nov 7, 2024 |
Direct |
F3, F4 |
| transaction |
RMD |
ResMed Common Stock |
Tax liability |
-$783K |
-3.1K |
-0.67% |
$252.38 |
461K |
Nov 11, 2024 |
Direct |
F5 |
| transaction |
RMD |
ResMed Common Stock |
Tax liability |
-$562K |
-2.23K |
-0.48% |
$252.38 |
459K |
Nov 11, 2024 |
Direct |
F6 |
| transaction |
RMD |
ResMed Common Stock |
Tax liability |
-$871K |
-3.45K |
-0.75% |
$252.38 |
455K |
Nov 11, 2024 |
Direct |
F7 |
| holding |
RMD |
ResMed Common Stock |
|
|
|
|
|
4.09K |
Nov 7, 2024 |
Lisette and Michael Farrell Family Trust |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
RMD |
ResMed Common Stock Options |
Options Exercise |
$0 |
-14.7K |
-100% |
$0.00 |
0 |
Nov 7, 2024 |
ResMed Common Stock |
14.7K |
$84.98 |
Direct |
F8, F9 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: